Submitted: 15 Oct 2015
Accepted: 12 Dec 2015
ePublished: 30 Jan 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Int J Phytocos Nat Ingred. 2016;3(1): 2.
doi: 10.15171/ijpni.2016.02
  Abstract View: 6263
  PDF Download: 4631

Original Research

A Clinical Trial with AtopisTM Cream for the Treatment of Mild to Moderate Eczema

Iona Elizabeth Weir*, Jhanna Pamela Molina, Simon Carson


BACKGROUND: Eczema is a common, chronic inflammatory skin disease characterized by itchy red rashes and scaly skin that can significantly affect the quality of life of patients. Moisturizing creams and emollients are often used to combat dryness and inflammation. The aim of this study was to demonstrate the efficacy of a topical study product in reducing the appearance and symptoms of eczema. OBJECTIVE: We performed an open-label, adaptive-design, pilot study evaluating the efficacy of the AtopisTM product in reducing the appearance of eczema lesions and reducing the symptoms of itching, scaling, and redness.

METHODS: Healthy subjects aged 18–75 years with mild to moderate eczema, which was determined at screening visit, were enrolled in the study. Subjects topically applied the AtopisTM study product twice daily on areas identified with skin lesions for 5 weeks. On a daily basis, subjects completed the Visual Analog Scale for eczema symptoms — itching, scaling, and redness. Dermatologic assessments for severity and size of lesions and Severity Scoring of Atopic Dermatitis (SCORAD) were also assessed by a practitioner in the clinic at days 0, 7, 15, 30.

RESULTS: Forty subjects were screened and a total of 20 subjects completed the study. VAS Symptom Score for Itching demonstrated statistically significant decreases from baseline to Weeks 2, 3, and 4 (p=0.001, p=0.011, p=0.031, respectively). In addition, VAS Symptom Score for Scaling demonstrated statistically significant reductions from baseline to Weeks 2, 3, 4 (p=0.000, p=0.003, p=0.031, respectively). VAS Symptom Score for Redness displayed statistically significant decreases from baseline to all time points (p=0.005, p=0.001, p=0.043, respectively). Dermatologic assessments including SCORAD Index demonstrated statistically significant reductions from baseline (20.61) to Day 30 (10.26) (49.11%; p=0.04). Subjective measures of quality of life assessed through DLQI showed a statistically significant reduction of 48.03% from baseline (7.60) to Day 30 (3.95) (p=0.031).

CONCLUSION: Topical application of AtopisTM study product for five weeks appears to be effective for treatment of mild to moderate eczema as it significantly reduced the appearance of lesions as well as symptoms associated including itching, scaling, and redness. The study product was safe and tolerable for twice a day application as no adverse events were reported.

SOURCE OF FUNDING: Decima Health Ltd., Rangiora, New Zealand

Keywords: Atopis, eczema, clinical
Please cite this paper as: Weir I, Molina, J, Carson, S. A clinical trial with Atopis TM cream for the treatment of mild to moderate eczema. International Journal of Phytocosmetics and Natural Ingredients. 2016;3:02. doi:10.15171/ijpni.2016.02.
First Name
Last Name
Email Address
Security code

Abstract View: 6263

Your browser does not support the canvas element.

PDF Download: 4631

Your browser does not support the canvas element.